Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new one-year data showing that its investigational oral drug icotrokinra continues to demonstrate high rates of durable skin clearance and …
Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results Read More